phase
iii
trial
toxic
might
reveal
largescal
exposur
seen
accordingli
phase
iv
postmarket
studi
requir
pr
technolog
fda
licens
evalu
pr
method
need
perform
earli
product
process
develop
model
vitro
test
virus
bacteria
parasit
also
need
develop
time
fashion
ideal
least
log
reduct
pathogen
load
suggest
accept
level
efficaci
methodolog
peak
viral
load
window
period
howev
high
unit
per
millilit
high
viral
load
might
prevent
reduct
pathogen
load
level
transmit
infect
phase
iii
trial
demonstr
clinic
effici
clinic
difficult
mani
factor
decreas
phase
iii
trial
assess
feasibl
first
larg
studi
popul
might
necessari
see
statist
clinic
differ
sinc
initi
nat
assay
even
larger
cohort
requir
find
addit
benefit
pr
achiev
test
alon
risk
contamin
current
method
test
small
second
pr
techniqu
appli
blood
product
ie
cryoprecipit
given
patient
third
epidemiolog
multipl
transmiss
routesvector
present
patient
acquir
infect
make
difficult
prove
infect
came
blood
therefor
relianc
phase
iv
surveil
use
requir
evalu
subtl
risk
margin
benefit
elimin
compound
clearli
damag
labil
blood
compon
necessari
evalu
pr
procedur
gross
hemolysi
platelet
dysfunct
reduct
coagul
factor
activ
problem
avoid
subtl
damag
difficult
assess
radiolabel
cell
autolog
transfus
monitor
surviv
recoveri
use
evalu
clinic
efficaci
clinic
bleed
time
inadequ
assess
platelet
function
deliveri
oxygen
tissu
inadequ
assess
red
cell
function
treatment
techniqu
fda
current
favor
clinic
assess
bleed
use
criteria
challeng
pr
technolog
continu
increas
benefit
threat
level
decreas
techniqu
donor
select
collect
process
screen
test
methodolog
detect
limit
improv
addit
benefit
use
pr
techniqu
decreas
risk
recipi
decreas
pathogen
reduct
increas
develop
less
toxic
effici
techniqu
benefit
appar
new
transfusiontransmiss
pathogen
emerg
sar
ebola
viru
pr
technolog
develop
howev
likelihood
replac
pathogenscreen
test
expect
anticip
rather
technolog
complement
exist
protocol
numer
method
cultiv
variou
stage
develop
use
solvent
deterg
pathogen
reduct
plasma
wide
studi
methodolog
current
use
across
europ
method
includ
photosensit
chemic
interact
pathogen
dna
andor
rna
crosslink
follow
exposur
uva
visibl
light
thu
inactiv
nucleic
acid
alkyl
agent
ethyleneimin
pr
technolog
also
crosslink
nucleic
acid
requir
light
activ
interest
side
benefit
technolog
white
cell
also
inactiv
thu
potenti
elimin
risk
transfusionassoci
graftversushost
diseas
tagvhd
chapter
discuss
recent
develop
address
technolog
either
use
like
use
near
futur
solvent
deterg
sd
treatment
disrupt
membran
envelop
viru
bacteria
eukaryot
infect
lost
via
action
mani
combin
tri
nbutyl
phosphat
tnbp
ethyl
ether
organ
solvent
tween
sodium
cholat
triton
nonion
deterg
use
past
sd
combin
often
use
tnbp
triton
chemic
reaction
nonselect
agent
must
remov
final
product
transfus
molecular
structur
tnbp
shown
figur
compound
act
organ
solvent
remov
lipid
sd
process
extract
sequest
separ
micellar
colloid
phase
molecular
structur
polyoxyetheleneptoctylphenol
triton
shown
figur
nonion
deterg
disrupt
lipid
bilay
easier
extract
stabil
tnbp
histori
sd
viral
inactiv
technolog
first
licens
treatment
clot
factor
concentr
combin
ethyl
ether
tween
found
effect
inactiv
hbv
nanbhv
factor
viii
ix
concentr
minim
loss
activ
tnbp
sodium
cholat
shown
effect
inactiv
hbv
nanbhv
hiv
sd
technolog
first
develop
use
sd
treatment
shown
effect
log
viral
load
reduct
spike
sampl
sdtreat
plasma
coagul
factor
profil
similar
untreat
ffp
remov
addit
occur
effici
period
approxim
unit
solvent
deterg
fresh
frozen
plasma
sdffp
transfus
without
signific
advers
sequela
sdffp
use
germani
switzerland
austria
belgium
franc
netherland
norway
sinc
earli
initi
test
use
tnbp
organ
solvent
triton
nonion
deterg
treat
blood
product
addit
incub
plasma
hour
pathogen
reduct
achiev
log
reduct
hbv
log
reduct
hcv
log
reduct
hiv
franc
tnbp
octoxynol
evalu
pr
agent
found
similar
coagul
factor
activ
compar
untreat
ffp
countri
europ
sdffp
complet
replac
convent
ffp
system
mutagen
reproduct
abnorm
note
use
sdtreat
product
wide
vari
product
use
technolog
includ
commerci
factor
viii
concentr
factor
ix
concentr
prothrombin
complex
commerci
factor
vii
fibrinogen
protein
c
factor
xi
antithrombin
iii
fibrin
glue
imig
ivig
antid
igg
hbvig
cmvig
rsvig
antitetanu
monoclon
antibodi
use
treatment
malign
prothrombin
complex
plasma
doubl
viru
elimin
procedur
develop
decreas
risk
transmiss
hav
procedur
involv
use
monoclon
antibodi
affin
chromatographi
nanofiltr
heat
ultraviolet
light
combin
solvent
deterg
sd
procedur
howev
discov
ineffect
nonenvelop
virus
us
develop
cost
sd
plasma
never
fulli
recov
hospit
market
use
product
peak
usag
report
occurr
thrombosi
andor
hemorrhag
use
sdffp
liver
transplant
patient
markedli
decreas
usag
us
cost
risk
administr
problem
caus
declin
use
sdffp
us
fewer
risk
note
europ
use
continu
inde
sd
technolog
wide
use
virucid
method
world
dose
sdtreat
product
given
even
though
sd
plasma
continu
licens
product
us
last
lot
made
avail
europ
extens
studi
neonat
infant
pregnant
women
yet
report
mani
step
requir
manufactur
sdffp
approxim
l
donor
process
simultan
techniqu
design
singl
donor
process
ffp
quickthaw
pass
filter
filtrat
addit
one
serv
remov
cell
cell
fragment
membraneassoci
virus
assur
aggregatefre
solut
plasma
treat
tnbp
triton
hour
castoroil
extract
phase
separ
perform
remov
tnbp
follow
clear
filtrat
triton
remov
hydrophob
interact
chromatographi
addit
steril
filtrat
mm
perform
treat
ffp
asept
fill
ml
aliquot
bag
seal
fast
frozen
store
qualiti
control
batch
releas
transfus
impair
viral
inactiv
seen
protein
concentr
mgml
lipid
level
mgdl
triglycerid
mgdl
cholesterol
plasma
protein
deriv
prepar
plasmaderiv
product
two
addit
step
perform
first
prior
sd
treatment
cohnoncley
fraction
procedur
util
recov
plasma
batch
fraction
effect
adequ
pathogenreduct
techniqu
transmiss
viral
infect
occur
batch
product
infus
postprocess
recipi
ivig
product
frequent
incid
infect
follow
infus
minim
degre
protect
given
fraction
although
decreas
viral
particl
titer
occur
log
howev
second
step
ph
treatment
requir
final
filtrat
step
decreas
aggreg
inactiv
envelop
nonenvelop
virus
log
postresidu
concentr
tnbp
triton
present
final
product
sever
commerci
manufactur
follow
tnbp
undetect
batch
batch
contain
mgml
tnbp
triton
undetect
batch
batch
contain
mgml
octapharma
product
octapla
w
studi
vitex
product
viplassd
w
reveal
less
ppm
tnbp
quantiti
one
lot
contain
ppm
triton
residu
ppm
two
lot
contain
ppm
efficaci
pathogen
reduct
initi
licensur
viplassd
w
viral
inactiv
rate
report
vesicular
stomat
viru
vsv
log
sindbi
sin
viru
log
hiv
log
bovin
viral
diarrheal
viru
bvdv
log
hbv
log
hcv
log
reduct
activ
virus
nonenvelop
virus
less
easili
inactiv
show
much
lower
log
reduct
hav
log
reduct
viral
particl
lead
outbreak
factor
viii
product
seroconvers
also
note
parvoviru
benefit
broadspectrum
activ
sd
treatment
envelop
pathogen
pick
routin
screen
assay
inactiv
techniqu
exampl
includ
hiv
type
variant
hbv
antibodi
nonenvelop
virus
final
product
might
protect
recipi
pathogen
protect
acquir
hav
infect
occur
result
presenc
antibodi
final
sd
product
concentr
antihav
antibodi
pool
sdffp
time
prophylact
dose
concentr
antibodi
protect
recipi
hav
infect
sdffp
antibodi
concentr
seen
ivig
use
treat
chronic
infect
antibodi
concentr
similarli
protect
recipi
acquir
parvoviru
thu
antihav
titer
iuml
titer
iuml
thought
provid
protect
respect
organ
screen
nat
anoth
way
decreas
transfus
transmiss
copi
number
low
copiesml
pathogen
detect
puriti
product
potenc
goal
prtreat
plasma
state
fda
activ
coagul
factor
mgml
fibrinogen
sdffp
meet
goal
lot
test
coagul
activ
rang
uml
factor
v
vii
x
xi
xii
mgml
fibrinogen
even
though
sdffp
activ
uml
clot
factor
approxim
lost
individu
factor
compar
untreat
ffp
feel
loss
requir
increas
number
transfus
sdffp
achiev
clinic
efficaci
standard
ffp
could
increas
risk
noninfecti
secondari
increas
transfus
requir
protein
decreas
sdffp
plasmin
inhibitor
decreas
decreas
decreas
anticoagul
factor
lead
increas
clot
risk
patient
defici
factor
absent
sdffp
clinic
signific
lack
enzym
acut
ill
patient
unknown
therapi
avail
patient
congenit
defici
enzym
year
us
six
patient
undergo
orthotop
liver
transplant
variou
underli
caus
endstag
liver
diseas
die
thrombot
hemorrhag
event
known
occurr
caus
coincident
shortli
episod
use
sdffp
plascsd
fell
disfavor
us
last
lot
made
studi
uk
show
equal
efficaci
sdffp
ffp
germani
openheart
surgeri
use
sdffp
ffp
compar
demonstr
equival
improv
relat
hemostasi
fibrinolysi
effect
viral
pathogen
vaccinia
shown
rel
resist
sd
treatment
even
though
envelop
viru
intracellular
nonenvelop
form
exist
infecti
activ
intracellular
particl
potenti
lead
infect
studi
impli
normal
envelop
virus
might
still
infecti
resist
sd
treatment
intracellular
environ
sd
techniqu
inactiv
nonenvelop
virus
year
outbreak
hav
occur
worldwid
factor
viii
ix
concentr
difficult
evalu
secondari
increas
incid
gener
popul
antibodi
pool
process
plasma
might
protect
recipi
transmiss
nanofiltr
use
remov
nonenvelop
virus
reduct
factor
vii
von
willebrand
factor
vwf
also
seen
higher
titer
antibodi
virus
present
final
blood
product
passiv
immun
might
acquir
sd
technolog
use
cellular
product
plasma
membran
disintegr
toxic
associ
sd
technolog
compound
interact
nucleic
acid
mutagen
becom
concern
present
mutagen
compound
lead
genotox
carcinogen
toxic
reproduct
system
compound
interact
membran
lipid
protein
advers
affect
cellular
function
reaction
occur
process
must
ensur
compound
present
final
product
administ
patient
risk
associ
sd
treatment
also
includ
toxic
chemic
addit
per
se
evalu
toxic
triton
lethal
dose
anim
kill
ld
use
triton
anim
studi
ld
gkg
via
oral
rout
ld
mgkg
intraperiton
intraven
rout
lowest
toxic
found
mgkg
mice
mgkg
rat
ld
mgkg
mice
mgkg
rat
mutagen
potenti
embryo
toxic
teratogen
potenti
demonstr
ttp
patient
could
theoret
receiv
l
plassd
triton
mgkg
well
toxic
level
chemic
reaction
nonselect
agent
must
remov
final
product
transfus
present
process
techniqu
often
detect
tnbp
triton
final
blood
product
benefit
mani
benefit
sd
treatment
lie
fact
addit
pathogen
reduct
process
unlik
degrad
plasma
protein
coagul
factor
loss
clinic
signific
loss
activ
seen
multipl
studi
thirti
percent
activ
requir
maintain
normal
hemostasi
envelop
virus
inactiv
process
transmiss
virus
seen
transfus
unit
studi
us
patient
hive
abdomin
pain
nausea
vomit
chill
headach
wheez
fever
hypertens
averag
recoveri
clot
factor
studi
popul
futur
studi
necessari
evalu
safeti
use
product
neonat
infant
pregnant
women
studi
evalu
statisticalclin
relev
decreas
infect
transmiss
risk
would
requir
hundr
thousand
cohort
group
undertaken
would
requir
multicent
trial
sever
year
sdffp
still
fda
licens
howev
time
sdffp
use
us
cost
produc
evalu
sdffp
involv
filter
track
extract
monitor
residu
pathogen
chemic
agent
addit
step
addit
increas
cost
product
three
four
time
untreat
ffp
previou
costeffect
analys
suggest
sdffp
cost
go
us
per
qualiti
life
year
qali
gain
argu
take
account
decreas
incid
transfusionrel
acut
lung
injuri
trali
sdffp
cost
would
decreas
us
per
qali
save
incid
trali
sdffp
neglig
given
dilut
affect
pool
plasma
aspect
medicin
accept
procedur
typic
cost
less
per
qali
gain
ie
cholesterol
reduct
coronari
arteri
bypass
aspect
transfus
medicin
howev
highcost
safeti
measur
adopt
reduc
risk
transfusiontransmit
diseas
cost
program
rang
million
per
qali
procedur
includ
autolog
donat
well
antigen
assay
hiv
cost
therefor
determin
factor
consid
reject
accept
sd
technolog
unipla
w
anoth
product
current
avail
unipla
w
solvent
detergenttr
univers
plasma
antia
antib
isoagglutinin
antibodi
remov
product
immun
complex
antia
antib
antibodi
solubl
b
antigen
hydrophob
remov
sd
treatment
total
protein
coagul
factor
unipla
w
similar
sdffp
publish
studi
patient
seroconvert
hiv
htlv
hbc
cmv
hav
parvoviru
seroposit
two
studi
show
equival
efficaci
unipla
w
octipla
w
openheart
surgeri
although
unipla
w
addit
benefit
compat
blood
group
studi
recommend
determin
unipla
w
otherwis
equival
standard
sd
phenothiazinium
dye
methylen
blue
methylen
blue
mb
first
synthes
caro
bernsthen
synthes
parent
ring
system
current
compound
administ
oral
antisept
disinfect
antidot
nitrat
poison
mb
use
treatment
methemoglobinemia
locat
surgic
site
valid
properli
follow
medic
prescript
longterm
use
human
associ
advers
effect
treat
methemoglobin
toxic
mb
instrument
cure
malaria
two
patient
demonstr
mb
could
inactiv
hsv
vaccinia
expos
light
nucleic
acid
found
target
mb
oxygen
found
necessari
reaction
photodynam
activ
reaction
sinc
mb
known
photochem
degrad
dna
use
mb
viral
inactiv
plasma
first
describ
ideal
photochem
dye
first
need
penetr
membran
whether
pathogen
plasma
membran
inactiv
intraa
well
extracellular
pathogen
second
adher
predomin
exclus
nucleic
acid
compound
littl
damag
red
blood
cell
third
sinc
hemoglobin
absorb
light
wavelength
less
nm
ideal
photocompound
absorb
light
wavelength
last
unbound
dye
caus
excess
damag
rbc
compound
need
activ
presenc
light
inact
blood
compon
storag
phenothiazin
dye
favor
unwant
cell
damag
limit
ensur
light
exposur
occur
initi
treatment
complet
contrast
sd
techniqu
reaction
ceas
pr
compound
remov
last
year
bacteri
tropic
diseas
ie
malaria
treat
mb
past
year
specif
antibiot
pathogen
develop
use
mb
decreas
renaiss
interest
pathogen
reduct
develop
plasmodium
falciparum
demonstr
increas
incid
chloroquin
resist
drugresist
bacteria
eg
mrsa
vre
multidrug
resist
tuberculosi
becom
common
opportunist
organ
hiv
patient
widespread
mechan
action
mb
bind
dna
two
way
depend
ionic
strength
concentr
mg
mb
bind
outsid
dna
helix
intercal
rung
helix
precis
mode
action
guaninespecif
cleavag
solut
lack
oxygen
environ
direct
electron
transfer
probabl
respons
strand
breakag
via
direct
cleavag
phosphodiest
bond
oxygenrich
solut
reactiv
oxygen
speci
io
oh
superoxid
gener
mb
peak
absorpt
nm
exposur
light
wavelength
produc
type
redox
reaction
type
ii
photodynam
photooxid
interact
mb
also
bind
viral
core
protein
shown
caus
damag
bacteria
proteu
mirabili
rbc
membran
protein
bacteria
hemoglobin
reduc
mb
convert
leukomethylen
form
neither
photosensit
intercalat
maximum
absorb
nm
mb
technolog
shown
inactiv
envelop
nonenvelop
virus
howev
given
hydrophob
natur
concentr
mm
compound
penetr
plasma
membran
andor
inactiv
intracellular
virus
formal
chemic
name
mb
bi
dimethylamino
chlorid
class
thiazin
dye
structur
formula
mb
shown
figur
leukobas
inact
form
shown
figur
mb
lipophil
polaritycharg
make
compound
hydrophil
reason
mb
easili
penetr
membran
studi
mb
bind
organ
compound
show
attach
preferenti
dna
negativelycharg
lipid
albumin
electr
neutral
lipid
bind
dna
negativelycharg
lipid
bind
respect
polyguanin
solut
account
remain
bind
particular
studi
initi
research
walter
reed
medic
center
mbtreat
plasma
becam
routin
use
countri
europ
still
use
decontamin
method
million
unit
transfus
untoward
event
mb
use
marker
surgeri
reduc
methemoglobin
much
mg
tid
ifosfamideinduc
encephalopathi
mgkg
septic
shock
given
patient
although
mb
use
much
higher
concentr
paul
ehrlich
institut
refus
licens
mbtreat
plasma
toxic
concern
advers
reaction
associ
mb
includ
burn
sensat
mouth
nausea
vomit
diarrhea
gastriti
larg
dose
caus
abdomin
chest
pain
headach
profus
sweat
mental
confus
pain
urin
methemoglobinemia
see
materi
safeti
data
sheet
ref
lifethreaten
clinic
situat
howev
advers
event
outweigh
lifesav
benefit
mb
two
differ
proprietari
method
process
ffp
mbpathinact
mb
w
baxter
macotron
w
macopharma
current
use
europ
procedur
gener
mb
treatment
plasma
util
mm
concentr
mb
follow
exposur
red
light
nm
fluenc
rate
mwcm
freez
thaw
unit
liber
intracellular
organ
one
studi
process
three
unit
time
pass
content
unit
membran
filtrat
system
filtrat
dri
tab
mb
mg
place
line
mb
dissolv
filtrat
approxim
jcm
less
minut
appli
nm
peak
l
light
concentr
mm
mb
unit
comput
control
procedur
process
mb
mm
concentr
fluenc
jcm
product
store
need
unit
thaw
transfus
manner
untreat
ffp
efficaci
efficaci
mb
reduct
increas
presenc
oxygen
process
demonstr
abil
inactiv
envelop
virus
dna
rna
genom
hiv
log
vsv
log
nonenvelop
virus
larg
capsid
pore
inactiv
ie
wnv
log
reduct
howev
nonencapsul
virus
tightli
interdigit
capsid
protein
eg
encephalomyocard
viru
inactiv
littl
bacteri
inactiv
observ
virucid
phototherapeut
condit
mb
effect
gramposit
gramneg
organ
candida
albican
trypanosoma
brucei
also
inactiv
mb
difficulti
penetr
plasma
membran
intracellular
organ
inactiv
viabil
red
cell
mb
use
rbc
product
decreas
day
storag
mb
red
blood
cell
lyse
addit
mbtreat
rbc
membran
show
dramat
increas
ion
leakag
mb
bind
igg
albumin
serum
protein
might
alter
rbc
membran
attach
membran
protein
despit
concern
advers
event
mb
long
histori
use
minim
toxic
problem
secondari
bind
protein
coagul
factor
fibrinogen
inactiv
mb
treatment
plasma
loss
activ
thought
secondari
oxid
histidin
residu
amino
acid
mb
also
bind
alpha
subunit
fibrinogen
result
lower
plateletreceptor
bind
result
mb
inactiv
intracellular
pathogen
white
blood
cell
mb
treatment
blood
product
reduc
incid
tagvhd
rbc
onehalf
mb
ad
bound
membran
protein
locat
within
rbc
compound
within
rbc
reduc
leukobas
form
neither
intercal
photosensit
bind
mb
rbc
surfac
protein
also
increas
ion
permeabl
membran
mb
also
inactiv
glutathion
reductas
decreas
red
blood
cell
abil
handl
oxid
toxic
effect
decreas
life
expect
red
cell
toxic
anim
studi
reveal
ld
oral
rout
mgkg
intraperiton
dose
mgkg
rat
mice
studi
oral
ld
shown
mgkg
indic
low
toxic
compound
mb
report
carcinogen
howev
toxocolog
properti
fulli
investig
concentr
use
clinic
practic
toxic
appear
minim
may
relat
final
concentr
bag
micromolar
level
molar
level
research
toxolog
properti
mb
need
amotosalen
compound
known
photosensit
first
use
around
ancient
egypt
india
treat
depig
lesion
chemic
obtain
parsley
parsnip
st
john
wort
appli
skin
expos
sunlight
caus
skin
damag
reepitheli
repigment
skin
oscar
raab
observ
paramecia
place
acrydin
dye
die
exposur
light
unaffect
light
exposur
occur
subsequ
compound
identifi
furocoumarin
group
includ
psoralen
modern
era
furocoumarin
appli
biolog
system
treat
variou
skin
tumor
condit
deactiv
microorgan
well
employ
research
tool
increas
knowledg
nucleic
acid
amotosalen
synthet
psoralen
specif
engin
inactiv
pathogen
blood
product
psoralen
natur
occur
heterocycl
compound
common
numer
plant
mention
addit
amin
side
chain
compound
becom
water
solubl
increas
affin
nucleic
acid
specif
characterist
necessari
psoralen
use
inactiv
microorgan
blood
product
includ
chemic
puriti
activ
upon
light
exposur
preferenti
retain
target
organ
rapidli
excret
elim
minim
toxic
addit
chemic
high
quantum
yield
photochem
event
hundr
psoralen
evalu
amotosalen
chosen
excel
activ
pathogen
minim
impact
blood
product
essenti
fulfil
criteria
amotosalen
also
known
use
inactiv
pathogen
plasma
platelet
exposur
uva
light
wavelength
nm
use
red
cell
concentr
hemoglobin
absorb
uva
light
amotosalen
work
via
threestep
chemic
reaction
chemic
initi
intercal
strand
dna
rna
exposur
uva
light
molecul
bind
olefin
moieti
pyrimidin
base
thymidin
cytidin
uridin
form
monoadduct
monoadduct
caus
helix
unwind
slightli
continu
exposur
uva
light
allow
second
adduct
form
result
crosslinkag
nucleic
acid
becom
nonfunct
crosslinkag
perman
replic
longer
occur
process
occur
singlestrand
nucleic
acid
structur
form
hairpin
turn
loop
allow
close
proxim
pyrimidin
base
thu
make
avail
crosslinkag
thu
pathogen
white
blood
cell
contain
blood
product
inactiv
figur
tabl
ceru
corpor
develop
call
helinx
technolog
combin
helinx
technolog
compound
adsorpt
devic
cad
result
system
known
intercept
blood
system
figur
cad
compos
activ
charcoal
diethyl
benzen
matrix
place
porou
contain
devic
locat
blood
product
storag
bag
scaveng
amotosalen
photoproduct
addit
step
necessari
platelet
system
work
best
plasma
concentr
platelet
bag
lower
ad
platelet
addit
solut
pa
iii
amotosalen
ad
plasma
platelet
concentr
mmml
mgml
agit
bag
illumin
jcm
uva
light
plasma
andor
platelet
subsequ
expos
cad
adsorb
excess
amotosalen
photoproduct
product
readi
storag
transfus
toxicolog
studi
amotosalen
involv
evalu
chemic
photoproduct
present
plasma
exposur
uva
light
studi
report
ciaravino
et
al
includ
evalu
reproduct
geno
carcino
phototox
well
acut
repeat
dose
toxic
photochem
treat
plasma
result
reproduct
chang
genotox
identifi
vitro
assay
bacteri
mutagen
assay
chromosom
aberr
assay
mous
lymphoma
assay
follow
vivo
assay
mous
micronucleu
assay
unschedul
dna
synthesi
assay
use
photochem
treat
plasma
without
cad
howev
photochem
process
singl
unit
time
without
cad
two
six
assay
posit
genotox
author
attribut
abund
excess
amotosalen
present
high
concentr
much
higher
expect
clinic
dose
part
studi
evalu
carcinogenesi
use
heterozyg
transgen
mice
unlik
homozyg
transgen
mice
develop
tumor
month
age
heterozyg
mice
develop
tumor
month
heterozyg
mice
expos
high
dose
amotosalen
photoproduct
intraven
month
increas
tumor
heterozyg
transgen
mice
phototox
demonstr
despit
residu
amotosalen
level
mgkg
addit
studi
assess
vein
irrit
neoantigen
neg
amotosalen
alon
produc
cn
effect
concentr
greater
estim
clinic
exposur
mgkg
electrocardiogram
chang
identifi
dose
higher
phototox
occur
dose
higher
estim
clinic
dose
genotox
occur
three
six
assay
expect
vitro
assay
due
intercal
behavior
amotosalen
base
studi
amotosalen
appear
safe
use
blood
compon
manner
dosag
intend
addit
toxicolog
studi
determin
advers
effect
amotosalen
blood
product
vitro
vivo
requir
numer
studi
perform
platelet
concentr
use
variou
endpoint
determin
viabil
photochem
treat
platelet
vitro
studi
found
process
intercept
blood
system
insignific
dropin
rang
number
platelet
present
bag
due
increas
amount
platelet
sampl
necessari
meet
demand
studi
requir
process
platelet
photochem
treatment
involv
manipul
platelet
three
differ
bag
agit
need
mix
amotosalen
platelet
expos
amotosalen
photoproduct
compound
absorpt
devic
moog
et
al
studi
singledonor
platelet
concentr
contain
mean
platelet
count
complet
photochem
treatment
pct
mean
platelet
count
repres
loss
also
moog
studi
signific
decreas
ph
identifi
pct
mean
drop
compar
control
howev
ph
level
well
requir
limit
requir
europ
ph
remain
end
studi
day
storag
glucos
decreas
mgdl
separ
plasma
follow
addit
intersol
pa
iii
remain
essenti
postpct
mgdl
expect
storag
glucos
continu
decreas
lactat
dehydrogenas
ldh
rise
signific
increas
ldh
evid
pct
indic
platelet
lysi
activ
subsequ
howev
ldh
level
remain
stabl
throughout
storag
hsr
decreas
prepar
pct
howev
platelet
appear
achiev
normal
hemostasi
upon
transfus
paramet
apoptosi
function
activ
platelet
examin
jansen
et
al
includ
pselectin
aggreg
studi
hypoton
shock
respons
annexin
v
caspas
activ
pct
caus
elev
pselectin
although
level
rise
time
storag
similar
control
chang
hsr
signific
studi
compar
control
caspas
activ
annexin
v
express
unchang
suggest
apoptosi
stimul
decreas
platelet
aggreg
signific
pct
howev
storag
compar
control
aggreg
studi
use
collagen
thrombin
decreas
use
adp
chang
vari
extent
studi
studi
extent
techniqu
result
french
valid
studi
consist
find
studi
also
investig
longer
storag
time
find
vitro
platelet
paramet
remain
within
satisfactori
rang
day
author
suggest
might
possibl
extend
expir
date
pct
platelet
day
chang
induc
pct
process
might
alway
significantli
differ
control
vitro
platelet
paramet
remain
within
guidelin
set
variou
regulatori
agenc
appear
adequ
clinic
use
one
vivo
studi
look
pct
platelet
surviv
follow
radiolabel
treat
autolog
platelet
normal
span
platelet
surviv
broad
rang
day
recoveri
recoveri
pctcad
platelet
lifespan
day
although
within
lower
rang
normal
significantli
lower
control
find
consist
studi
addit
author
found
vitro
studi
label
dissoci
higher
pct
platelet
control
platelet
vivo
studi
yield
similar
data
result
show
small
chang
might
might
signific
compar
control
although
perform
still
within
regulatori
guidelin
medic
accept
rang
endpoint
studi
includ
postplatelet
count
variou
time
period
number
transfus
requir
given
time
period
number
advers
reaction
platelet
refractori
bleed
episod
studi
also
look
possibl
antibodi
amotosalen
neoantigen
two
larg
vivo
studi
eurosprit
platelet
recoveri
thrombocytopenia
europ
sprint
platelet
recoveri
thrombocytopenia
usa
trial
report
similar
result
sprint
trial
nationwid
studi
enrol
thrombocytopen
patient
random
pctcadtreat
platelet
standard
platelet
platelet
singl
donor
unit
collect
apheresi
eurosprit
trial
design
similarli
studi
found
cci
correct
count
increment
lower
patient
treat
pct
platelet
find
studi
explain
lower
platelet
number
pct
unit
sprint
trial
howev
correct
lower
dose
per
unit
infus
investig
found
signific
differ
pctcad
platelet
standard
platelet
unit
reason
patient
treat
pct
platelet
unit
requir
transfus
time
bleed
refractori
essenti
control
patient
treat
pct
unit
trial
sprint
trial
transfus
reaction
fewer
patient
treat
pctcad
platelet
versu
antibodi
amotosalen
neoantigen
identifi
therefor
pctcad
treat
platelet
consid
function
safe
effect
control
platelet
patient
summari
platelet
studi
whole
demonstr
pctcad
platelet
appear
accept
altern
untreat
platelet
given
ad
safeti
measur
pr
process
due
loss
fraction
platelet
process
number
platelet
transfus
requir
patient
may
slightli
higher
function
ffp
pctcad
also
valid
phase
iii
trial
norway
germani
support
largescal
process
ffp
pool
maximum
quantiti
ml
allow
three
unit
ffp
produc
per
pctcad
process
assay
factor
ii
v
vii
viii
ix
x
xi
xiii
protein
c
antithrombin
iii
fibrinogen
assay
manufactur
laboratori
fibrinogen
factor
viii
level
maintain
prepctcad
level
factor
ii
v
vii
ix
x
xi
xiii
protein
c
antithrombin
iii
antiplasmin
maintain
prepctcad
level
thu
quantiti
anticoagul
procoagul
factor
declin
minim
recal
declin
seen
pct
platelet
number
howev
clinic
trial
demonstr
pctcadtreat
plasma
factor
function
adequ
vivo
patient
acquir
congenit
coagulopathi
ttp
well
requir
warfarin
revers
hambleton
et
al
studi
healthi
volunt
donat
apheresi
plasma
half
group
treat
pctcad
half
process
usual
fashion
subsequ
subject
took
warfarin
day
factor
vii
level
lower
mean
concentr
iuml
infus
l
either
pcttreat
untreat
plasma
two
week
later
process
repeat
subject
receiv
type
ffp
mean
peak
increment
iuml
factor
vii
identifi
pctcadtreat
standard
ffp
result
reveal
despit
mild
decreas
level
factor
pcttreat
ffp
factor
vii
level
increas
level
patient
either
pcttreat
untreat
plasma
addit
studi
measur
pt
determin
coagul
factor
function
chang
pt
level
close
reflect
drop
factor
vii
level
first
hour
decreas
similarli
control
test
patient
hour
ffp
infus
howev
pt
rebound
preinfus
level
pctcadtreat
ffp
patient
patient
treat
standard
ffp
anoth
studi
report
abstract
review
effect
pctcadtreat
ffp
patient
acquir
coagulopathi
due
liver
diseas
requir
treatment
ffp
sever
factor
level
evalu
pt
ptt
report
advers
event
describ
ptand
ptt
decreas
similarli
control
treat
patient
activ
bleed
stop
one
patient
given
pctcadtreat
ffp
von
willebrand
factor
studi
separ
anoth
studi
report
abstract
similarli
statist
differ
pctcadtreat
plasma
convent
ffp
recent
abstract
report
mintz
et
al
examin
efficaci
pctcad
plasma
ttp
patient
mean
time
remiss
remiss
rate
mean
number
exchang
relaps
rate
significantli
differ
control
p
valu
rang
patient
develop
new
antibodi
although
one
patient
seriou
advers
event
day
therapeut
plasma
exchang
describ
abstract
patient
remov
studi
recov
without
sequela
despit
event
author
conclud
pctcadtreat
ffp
perform
similarli
control
plasma
term
efficaci
safeti
therefor
like
advers
event
could
occur
untreat
plasma
well
thu
numer
clinic
trial
demonstr
ffp
treat
pctcad
appear
effect
standard
ffp
abil
amotosalen
reduc
pathogen
contain
unit
blood
platelet
plasma
littl
doubt
numer
studi
demonstr
minimum
greater
log
reduct
virus
bacteria
protozoan
test
whether
extraor
intracellular
experi
report
lin
et
al
typic
research
ad
high
level
pathogen
singledonor
platelet
unit
case
hiv
evalu
cellfre
cellassoci
viru
well
provir
hiv
duck
hepat
b
dhbv
bovin
viral
diarrhea
viru
bvdv
use
surrog
human
strain
hepat
b
hepat
c
repres
gramposit
staphylococcu
epidermidi
gramneg
klebsiella
pnemonia
bacteria
studi
inocul
colonyform
unit
cfu
ml
platelet
unit
treatment
bag
sampl
order
determin
viral
bacteri
titer
differ
level
uva
light
use
determin
appropri
level
pathogen
inactiv
base
studi
uva
frequenc
set
jcm
start
small
dose
allow
author
differenti
speed
effect
process
hiv
readili
elimin
provir
hiv
even
sensit
process
cellfre
cellassoci
hiv
high
level
bvdv
dhbv
also
readili
inactiv
jcm
klebsiella
bacteria
howev
resist
two
four
unit
still
infect
pct
jcm
experi
repeat
four
unit
neg
gramneg
bacteria
known
resist
pct
due
lipopolysaccharid
outer
membran
serv
inhibit
small
organ
molecul
amotosalen
howev
author
conclud
abil
process
reduc
bacteria
factor
greater
consid
success
clinic
presenc
high
titer
blood
product
would
highli
unlik
epidermidi
readili
inactiv
process
jcm
van
voorhi
et
al
conduct
similar
experi
cruzi
demonstr
effect
pctcad
inactiv
parasit
like
becom
concern
futur
lin
et
al
jordan
et
al
demonstr
effect
pathogen
reduct
latent
free
cmv
mice
anoth
experi
lin
et
al
look
sever
type
bacteria
includ
gramneg
gramposit
anaerob
aerob
spirochet
specif
treponema
pallidum
borellia
burgdorferi
spirochet
sensit
pctcad
process
variou
bacteria
examin
effect
inactiv
process
describ
abil
psoralen
amotosalen
reduc
pathogen
excel
howev
studi
need
fulli
explor
upper
limit
capac
pctcad
mg
dose
amotosalen
plu
jcm
reduc
pathogen
activ
might
import
pathogen
resist
process
klebsiella
pneumonia
parvoviru
safeti
amotosalenbas
pctcad
process
well
demonstr
shortterm
sever
phase
iii
clinic
trial
longterm
studi
necessari
determin
risk
particularli
carcinogenesi
amotosalenbas
process
platelet
current
review
us
fda
europ
process
platelet
receiv
ce
mark
valid
implement
countri
includ
franc
norway
costbenefit
analys
begun
initi
find
report
netherland
germani
conclud
cost
intercept
blood
system
platelet
compar
blood
safeti
intervent
nucleic
acid
test
current
intercept
blood
system
program
variou
stage
develop
regulatori
approv
process
numer
obstacl
beset
develop
photochem
system
red
cell
includ
problem
caus
absorpt
uva
light
hemoglobin
photochem
treat
red
cell
often
sustain
damag
result
hemolysi
potassium
leakag
storag
new
method
process
develop
one
method
develop
manufactur
amotosalen
base
compound
known
part
class
compound
known
frale
frangibl
anchor
linker
effector
tripartit
molecul
compos
nucleic
acid
anchor
effector
moieti
frangibl
linker
effector
moieti
bind
nucleic
acid
coval
frangibl
linker
break
form
inact
neg
charg
speci
prevent
bind
nucleic
acid
thu
render
dna
rna
nonfunct
complet
lightindepend
reaction
proce
due
shift
ph
occur
ad
red
blood
cell
concentr
process
develop
requir
addit
red
cell
concentr
mgml
incub
hour
room
temperatur
red
cell
incub
compound
absorpt
devic
cad
addit
hour
transfer
storag
contain
remov
residu
cad
remain
red
cell
throughout
storag
inform
publish
pathogen
reduct
abstract
form
earliest
abstract
cook
et
al
report
biolog
signific
differ
red
cell
store
day
although
degre
hemolysi
appear
vari
significantli
among
treat
unit
studi
evalu
rbc
recoveri
dog
mice
use
biotin
recoveri
techniqu
result
compar
control
year
later
cook
et
al
report
result
anoth
red
cell
studi
recoveri
dog
significantli
differ
control
addit
conduct
two
experi
one
involv
replac
dog
blood
volum
cell
involv
dog
receiv
twelv
transfus
month
concentr
experi
reach
mgml
thought
five
time
human
would
receiv
toxic
identifi
flow
cytometri
use
evalu
immunogen
identifi
antibodi
specif
earli
human
studi
find
similar
hambleton
et
al
found
greater
rbc
recoveri
human
transfus
autolog
blood
studi
perform
one
clinic
trial
reenrol
subject
second
trial
subject
thu
receiv
one
consecut
transfus
evalu
dat
antibodi
screen
crossmatch
data
remain
vivo
recoveri
hambleton
et
al
subsequ
perform
crossov
studi
found
statist
differ
control
red
cell
recoveri
treatment
phase
iii
clinic
trial
initi
base
preliminari
data
despit
promis
result
regard
efficaci
red
cell
patient
trial
halt
due
antibodi
format
cell
patient
requir
chronic
transfus
thalassemia
sicklecel
anemia
enter
random
doubleblind
crossov
studi
patient
receiv
total
six
transfus
number
unit
per
transfus
well
frequenc
transfus
determin
treat
physician
two
asymptomat
pediatr
patient
develop
antibodi
red
cell
transfus
pretransfus
iat
crossmatch
neg
despit
antibodi
evid
reduc
red
cell
surviv
monocyt
monolay
rbc
phagocyt
assay
neg
suggest
antibodi
like
clinic
signific
dat
patient
neg
hapten
inhibit
assay
glutathion
exhibit
inhibit
latter
use
buffer
process
alter
pathogenreduct
process
made
attempt
elimin
antibodi
problem
origin
protocol
mm
ad
mm
unbuff
gsh
stassinopoulo
et
al
alter
process
ad
mm
gsh
significantli
reduc
presenc
red
cell
sera
patient
develop
antibodi
ad
modifi
treat
red
cell
iat
neg
pathogen
reduct
use
modifi
process
remain
effect
modif
essenti
dilut
rather
elimin
neoantigen
presenc
red
cell
research
requir
determin
dilut
alon
adequ
prevent
alloimmun
red
cell
process
red
cell
regard
pathogen
reduct
system
appear
effect
cook
et
al
report
log
inactiv
depend
linearli
dose
ad
studi
evalu
pathogen
reduct
cellfre
hiv
cellassoci
hiv
duck
hepat
b
viru
bovin
viral
diarrhea
viru
herp
simplex
vesicular
stomat
viru
yersinia
enterocolitica
log
inactiv
rang
whether
level
inactiv
relat
level
detect
report
second
studi
cook
et
al
look
cellfre
hiv
duck
hepat
b
viru
bovin
viral
diarrheal
viru
enterocolitica
found
even
higher
level
inactiv
rang
yersinia
bovin
viral
diarrheal
viru
virus
reduc
level
detect
assay
overal
literatur
regard
frale
technolog
minim
due
earli
phase
technolog
develop
appear
effect
pathogenreduct
agent
red
cell
function
within
necessari
clinic
paramet
vitro
vivo
phase
iii
trial
hold
due
immun
reaction
two
patient
report
even
problem
antibodi
format
diminish
level
risk
antibodi
product
must
vanishingli
small
side
effect
pathogenreduct
process
must
less
risk
contract
infecti
diseas
erad
anoth
prpi
compound
also
disrupt
nucleic
acid
like
light
requir
reaction
therefor
use
treat
red
cell
compound
chemic
relat
binari
ethyleneimin
known
ethyleneimin
oligom
alter
molecul
cation
select
nucleic
acid
highli
water
solubl
molecul
small
readili
diffus
cell
membran
manufactur
claim
make
effect
nonlipid
envelop
virus
parvovirus
resist
heterocycl
compound
see
amotosalen
form
ionic
bond
nucleic
acid
activ
molecul
proton
aziridino
nitrogen
activ
form
alkyl
proxim
nucleophil
center
posit
guanin
dna
result
open
imidazol
ring
structur
guanin
creat
break
strand
creat
stop
messag
nucleic
acid
thu
inactiv
becom
useless
templat
binari
ethyleneimin
like
psoralen
use
nucleic
acid
research
sinc
develop
use
pathogen
reduct
blood
product
howev
occur
past
year
process
known
inactin
treatment
ad
creat
volvol
concentr
incub
room
temperatur
hour
remov
wash
unbuff
salin
level
limit
detect
use
hplc
ngml
unit
readi
storag
toxicolog
two
main
studi
chapman
butterwork
moor
describ
toxicolog
compound
react
nucleic
acid
ame
mous
lymphoma
assay
posit
indic
genotox
also
induc
unschedul
dna
synthesi
ud
rat
hepatocyt
cultur
howev
chromosom
assay
whole
anim
toxic
assay
neg
given
rat
intraven
high
blood
concentr
induc
ud
hepatocyt
suggest
effect
clearanc
pathway
compound
appear
excret
quickli
urin
second
studi
focus
reproduct
effect
conduct
rat
rabbit
male
femal
rat
regularli
dose
variou
quantiti
mate
anim
kill
gestat
day
examin
euthanasia
male
sperm
analysi
conduct
rabbit
known
sensit
model
reproduct
toxicolog
rat
second
studi
arm
initi
use
mate
femal
rabbit
dose
kill
gestat
day
abil
rat
becom
pregnant
impair
number
implant
site
number
fetus
number
fetal
loss
significantli
differ
found
control
fetal
abnorm
identifi
numer
sperm
characterist
evalu
male
none
significantli
differ
control
femal
rat
rabbit
receiv
highest
dose
demonstr
toxic
character
significantli
decreas
food
consumpt
decreas
weight
gain
fetus
rabbit
mother
receiv
highdos
significantli
increas
skelet
variat
howev
variat
clinic
signific
affect
viabil
fetus
effect
identifi
dose
regimen
mg
per
kilogram
weight
rabbit
mgkg
rat
wash
blood
ml
contain
mg
equival
mgkg
bodi
weight
person
level
time
lower
mgkg
dose
given
rat
base
cumul
mg
per
kg
figur
dose
time
less
therefor
even
given
individu
human
might
receiv
multipl
unit
time
dose
believ
far
less
requir
induc
reproduct
genotox
major
research
thu
far
use
inactiv
pathogen
unit
red
blood
cell
preclin
trial
purmal
et
al
studi
effect
pathogen
inactiv
use
incub
number
red
cell
paramet
includ
hemolysi
rbc
atp
intracellular
potassium
red
cell
surfac
antigen
rbc
atp
significantli
reduc
red
cell
compar
control
whether
incub
use
howev
level
atp
still
within
clinic
accept
rang
hemolysi
day
significantli
increas
compar
control
cell
incub
hour
inact
pipr
process
effect
intracellular
potassium
snyder
et
al
similar
result
lower
atp
treat
cell
clinic
signific
differ
hemolysi
versu
control
red
cell
group
also
studi
sodium
methemoglobin
complet
blood
count
cbc
lactat
glucos
signific
differ
control
cell
atp
level
also
lower
studi
aubuchon
et
al
author
also
note
lower
level
lactat
decreas
glucos
consumpt
cell
chang
interpret
metabol
slow
although
explan
provid
chang
within
accept
rang
clinic
significantli
differ
compar
control
result
three
studi
includ
vivo
studi
arm
evalu
day
storag
purmal
et
al
remov
red
blood
cell
baboon
doubl
label
cr
reinfus
autolog
anim
red
cell
surviv
day
storag
rang
control
cell
day
storag
red
cell
surviv
rang
control
cell
differ
surviv
time
statist
signific
snyder
et
al
studi
phase
ii
clinic
trial
use
healthi
human
volunt
reinfus
crradiolabel
blood
follow
treatment
day
storag
control
unit
process
similar
manner
vivo
surviv
cell
store
day
day
storag
surviv
control
statist
similar
day
storag
day
storag
mean
rise
hemoglobin
hour
day
infus
remain
unlabel
autolog
unit
red
blood
cell
also
evalu
result
statist
differ
control
valu
versu
gdl
valu
versu
gdl
vivo
portion
aubuchon
et
al
studi
evalu
surviv
red
cell
human
day
storag
determin
valu
statist
differ
cell
surviv
valu
also
similar
control
none
studi
found
evid
induc
neoantigen
subject
baboon
human
monitor
day
day
day
base
result
appear
safe
anim
peopl
least
short
term
chang
red
cell
paramet
within
accept
rang
extens
research
conduct
regard
pathogen
inactiv
capac
studi
specif
demonstr
exact
natur
action
viru
kinet
inactiv
well
demonstr
activ
presenc
high
low
titer
virus
one
initi
studi
evalu
effect
four
envelop
virus
six
nonenvelop
virus
cellassoci
virus
chosen
includ
wide
array
physiolog
characterist
size
structur
biochem
composit
whether
viru
cell
associ
cell
free
envelop
type
bvdv
pseudorabi
viru
prv
recogn
model
hcv
herp
viru
envelop
virus
includ
studi
sinbi
sv
viru
vesicular
stomat
indiana
viru
vsiv
nonenvelop
virus
includ
porcin
parvoviru
ppv
model
viru
vesicular
exanthema
swine
viru
vesv
model
hepat
e
norwalk
virus
remain
virus
includ
use
demonstr
wide
spectrum
activ
studi
inactiv
process
alter
use
sodium
thiosulph
st
acid
mop
chemic
stop
reaction
rather
wash
ensur
decreas
viral
cytotox
effect
due
alon
wash
addit
red
cell
unit
collect
three
differ
addit
solut
storag
media
viru
titer
determin
tissu
cultur
infecti
dose
tcid
assay
plaqueform
unit
assay
kinet
viral
reduct
determin
collect
sampl
hour
incub
result
studi
seen
figur
three
nonenvelop
vesv
foot
mouth
diseas
viru
fmdv
bluetongu
viru
btv
two
envelop
virus
sv
vsiv
reduc
level
detect
assay
within
hour
incub
virus
reduc
factor
rang
log
tcid
per
millilit
bvdv
prv
took
hoursto
reduc
level
detect
three
nonenvelop
virusesppv
hour
reduc
level
detect
reduct
factor
virus
log
tcid
per
millilit
log
pfu
per
millilit
respect
cellular
hiv
reduct
level
detect
took
hour
group
research
conduct
seri
experi
investig
inactiv
hiv
evalu
effect
structur
viru
em
abil
viru
enter
cell
treatment
revers
transcriptas
activ
treatment
addit
usual
demonstr
treatment
effect
via
tcid
assay
structur
viru
chang
abil
viru
infect
cell
remain
intact
treatment
howev
viral
revers
transcriptas
function
consist
alter
nucleic
acid
hiv
reduct
took
place
primarili
first
hour
decreas
level
detect
hour
largevolum
infect
requir
hour
decreas
level
detect
reduct
factor
vari
log
tcid
hour
anoth
studi
demonstr
effect
hbv
studi
west
nile
viru
mather
et
al
explor
surviv
viru
blood
store
usual
blood
bank
condit
found
although
viral
popul
decreas
time
unit
remain
infecti
throughout
day
storag
spike
hightit
viral
concentr
lowtit
spike
unit
noninfecti
day
dose
chosen
high
low
titer
base
limit
data
avail
donor
natur
wnv
pathogen
inactiv
techniqu
infect
infect
determin
pfu
assay
although
studi
demonstr
viral
surviv
whether
dose
present
would
suffici
caus
infect
human
known
addit
studi
demonstr
wnv
distribut
blood
componentsr
blood
cell
plasma
plateletsand
viru
infect
monocyt
may
harbor
cell
vivo
treatment
reduc
wnv
level
detect
assay
within
hour
hour
reduc
viru
factor
log
tcid
per
millilit
anoth
studi
group
compar
effect
gamma
radiat
cmvinfect
cell
use
model
latent
infect
white
cell
addit
demonstr
effici
cmvinfect
cell
experi
demonstr
gamma
irradi
despit
inactiv
white
cell
capac
actual
increas
cmv
replic
inactiv
bacteria
success
although
limit
evid
bacteri
contamin
blood
gener
occur
due
organ
skin
donor
time
collect
common
organ
therefor
skin
contamin
staphylococcu
epidemidi
propionibacterium
acn
organ
ubiquit
environ
also
common
clostridium
perfringen
pseudomona
fluorescen
pseudomona
putida
acinetobact
speci
yersinia
entercolitica
also
associ
transfusionrel
sepsi
thought
come
bacteremia
donor
yersinia
gastroenter
studi
use
variou
titer
organ
infect
red
blood
cell
unit
success
inactiv
major
organ
howev
studi
reveal
high
titer
organ
could
inactiv
acinetobact
iwoffii
johnsonii
inactiv
titer
less
cfuml
bacteria
persist
unit
infect
higher
titer
enterocolitica
p
fluorescen
demonstr
similar
resist
inactiv
higher
titer
studi
howev
earlier
studi
group
titer
cfu
chosen
simul
worsecas
scenario
base
report
clinic
level
detect
donat
blood
yersinia
cfuml
lower
level
bacteremia
norm
clinic
lack
pathogen
reduct
level
cfuml
relev
howev
question
upper
limit
effect
pathogenreduct
technolog
remain
concern
importantli
concentr
level
pathogen
blood
may
depend
organ
involv
abl
inactiv
mycoplasma
pneumonia
arthritidi
cfuml
even
organ
appear
remov
howev
remov
level
detect
protozoa
studi
b
microti
elimin
level
detect
hamster
given
blood
develop
identifi
infect
even
pcr
test
howev
hamster
mount
igg
antibodi
respons
surpris
given
inactiv
occur
nucleic
acid
level
leav
organ
antigen
place
protozoa
test
includ
p
falciparum
cruzi
effect
reduc
summari
demonstr
robust
viral
bacteri
inactiv
capac
use
sensit
pcr
method
highand
lowtit
infect
investig
reveal
higher
lower
limit
pathogenreduct
process
given
cost
implement
pathogenreduct
process
hope
would
process
would
reduc
pathogen
noninfecti
level
despit
initi
titer
addit
studi
need
evalu
pathogenreduct
process
clinic
set
condit
involv
mixtur
pathogen
clinic
relev
level
combin
white
cell
present
differ
concentr
determin
true
capac
pathogenreduct
process
two
phase
iii
studi
involv
patient
requir
acut
transfus
therapi
surgic
support
chronic
transfus
involv
sicklecel
thalassemia
patient
halt
due
develop
immun
respons
rbc
associ
clinic
find
immunogen
thu
problem
pathogenreduct
chemic
even
number
event
small
risk
immunogen
must
smaller
risk
infect
untreat
blood
small
take
research
time
determin
safe
effect
prpi
technolog
realli
riboflavin
also
known
vitamin
wide
investig
number
differ
perspect
past
year
extens
knowledg
compound
much
background
work
requir
develop
riboflavin
pathogenreduc
agent
blood
alreadi
report
numer
nutrit
studi
alreadi
perform
unna
et
al
investig
toxic
riboflavin
rat
found
excess
amount
riboflavin
taken
mouth
toxic
due
inabl
gastrointestin
system
absorb
suffici
quantiti
vitamin
toxic
observ
rat
intraperiton
inject
mgkg
result
renal
failur
due
yellow
concret
accumul
kidney
intraven
toxic
could
determin
due
low
solubl
riboflavin
zempleni
et
al
defin
pharmacokinet
oral
intraven
riboflavin
human
use
oral
dose
mg
intraven
dose
mg
base
numer
studi
perform
year
riboflavin
classifi
gra
gener
regard
safe
compound
also
known
mani
year
respons
riboflavin
light
damag
reaction
nucleic
acid
tsugita
et
al
determin
light
reaction
riboflavininactiv
srna
requir
presenc
oxygen
inactiv
tobacco
mosaic
viru
demonstr
inactiv
local
guanin
adenin
nucleotid
addit
compar
riboflavin
lumichrom
mb
found
riboflavin
effici
sensit
mechan
action
phototox
riboflavin
describ
joshi
time
photodynam
reaction
riboflavin
light
known
gener
superoxid
anion
radic
k
ho
damag
nucleic
acid
joshi
demonstr
singlet
oxygen
also
gener
reaction
lead
photooxid
nucleotid
guanin
thu
damag
nucleic
acid
two
type
photoreact
occur
type
photoreact
electron
excit
photosensit
biolog
substrat
reaction
oxygen
independ
substrat
concern
nucleic
acid
although
biolog
molecul
affect
well
type
ii
reaction
activ
photosensit
molecul
oxygen
result
format
oxygen
radic
singlet
oxygen
radic
respons
major
damag
nucleic
acid
result
strand
break
fragment
kumar
et
al
demonstr
effect
process
uv
light
alon
bacteria
virus
white
cell
addit
gener
oxygen
radic
photoreact
riboflavin
also
gener
breakdown
photoproduct
lumichrom
lumiflavin
ketoflavin
ketoflavin
flavin
mononucleotid
formylmethylflavin
lumichrom
lumiflavin
abund
product
other
present
small
amount
best
detect
hplc
lumichrom
toxic
genotox
evalu
vitro
vivo
experi
piper
et
al
vitro
genotox
evalu
use
ame
assay
neg
mous
fibroblast
incub
variou
concentr
lumichrom
highest
mm
limit
solubl
cytotox
identifi
vivo
portion
studi
involv
inject
mice
mgkg
lumichrom
iv
acut
toxic
identifi
major
photoproduct
riboflavinlumiflavinwa
evalu
ame
salmonella
assay
umu
test
so
chromotest
ame
umu
test
bacteri
genotox
test
system
so
chromotest
bacteri
colorimetr
assay
genotoxin
studi
riboflavin
lumiflavin
neg
genotox
howev
lumiflavin
expos
metabol
enzym
colon
liver
signific
mutagen
identifi
three
assay
studi
perform
order
ascertain
danger
pose
riboflavin
food
product
investig
mutagen
lumiflavin
yet
investig
blood
product
remain
photoproduct
present
small
concentr
often
react
reform
riboflavin
thu
less
like
effect
riboflavin
light
visibl
light
light
within
uv
spectrum
use
pathogenreduc
blood
product
howev
major
studi
report
thu
far
involv
platelet
platelet
unit
subject
riboflavin
light
process
decreas
concentr
due
dilut
riboflavin
solut
total
platelet
count
unchang
similar
control
remain
stabl
throughout
storag
one
studi
vitro
perform
characterist
treat
unit
significantli
differ
day
storag
differ
appear
due
metabol
chang
paramet
chang
significantli
photochem
treatment
mark
reduct
po
mild
increas
pselectin
express
treatment
also
appear
increas
glucos
consumpt
despit
differ
paramet
still
within
clinic
relev
limit
use
vivo
studi
necessari
determin
signific
vitro
find
recent
studi
look
sole
effect
riboflavin
light
process
platelet
produc
buffi
coat
method
use
commonli
europ
platelet
acquir
via
apheresi
numer
platelet
paramet
includ
platelet
integr
morpholog
biolog
activ
examin
result
similar
previou
studi
mark
decreas
po
photochem
treatment
expect
given
mechan
action
riboflavin
light
glucos
decreas
pselectin
express
lactat
increas
storag
ph
decreas
storag
period
remain
overal
chang
paramet
compar
control
number
still
within
defin
clinic
limit
suggest
platelet
would
function
investig
capac
riboflavin
light
reduc
pathogen
without
harm
product
earli
stage
primarili
involv
use
technolog
platelet
concentr
one
initi
studi
place
mm
riboflavin
storag
media
expos
nm
visibl
light
jcm
energi
dose
bovin
viral
diarrheal
viru
bvdv
model
hcv
use
infect
platelet
log
reduct
limit
detect
accomplish
infect
dose
log
use
jcm
energi
dose
log
reduct
identifi
initi
infect
dose
log
use
jcm
energi
dose
platelet
paramet
studi
minim
affect
compar
control
goodrich
et
al
look
bacteri
pathogen
reduct
platelet
riboflavin
mm
ad
unit
spike
logml
titer
epidermidi
escherichia
coli
aureu
b
cereu
k
pneumonia
illumin
time
jcm
uv
light
lowtit
experi
parallel
spike
unit
logml
titer
use
jcm
uv
light
signific
reduct
occur
rang
logml
reduct
even
low
titer
time
higher
level
expect
platelet
time
donat
thu
photoactiv
riboflavin
appear
adequ
pathogen
reduct
blood
product
time
experi
investig
riboflavin
light
red
blood
cell
unit
use
riboflavin
solut
nm
visibl
light
illumin
red
cell
spike
hiv
bvdv
psr
treat
signific
pathogen
reduct
occur
red
cell
paramet
examin
hemolysi
observ
experi
extens
studi
perform
riboflavin
level
mm
reach
mm
dilut
platelet
concentr
light
paramet
chosen
uv
light
jcm
output
rang
nm
porcin
parvoviru
ppv
ad
achiev
titer
log
tcid
cellassoci
cellfre
hiv
ad
titer
log
tcid
per
millilit
intracellular
hiv
ad
titer
tcid
per
millilit
wnv
ad
achiev
initi
titer
tcid
per
millilit
interfer
cytotox
determin
factor
result
gramneg
bacteria
repres
e
coli
gramposit
bacteria
repres
epidermidi
use
spike
unit
initi
titer
cfusml
hightit
arm
cfusml
lowtit
arm
vitro
platelet
paramet
measur
includ
ph
lactat
po
pco
platelet
count
hsr
swirl
score
pselectin
express
viral
reduct
level
observ
exceed
level
requir
close
window
period
hiv
reduc
titer
intracellular
freeand
cellassoci
hiv
level
detect
reduct
wnv
occur
extent
believ
close
total
virem
period
wnv
due
inactiv
log
tcid
per
millilit
parvoviru
also
reduc
level
detect
reduct
factor
log
tcid
amount
reduct
could
close
chronic
phase
transmiss
window
human
parvoviru
infect
last
viru
difficult
erad
titer
infect
donor
exceed
genom
equival
per
millilit
howev
level
logml
thought
infecti
bacteri
strain
reduc
level
detect
high
titer
arm
studi
low
titer
arm
concentr
remain
cultur
neg
day
storag
summari
riboflavin
photochem
activ
light
produc
mark
robust
pathogen
reduct
platelet
red
blood
cell
compound
riboflavin
gener
consid
safe
question
remain
howev
regard
photoproduct
produc
process
studi
photoproduct
limit
lumichrom
appear
safe
studi
thu
far
research
requir
lumiflavin
question
addit
research
also
necessari
earli
studi
indic
effect
process
platelet
red
blood
cell
clinic
accept
research
pathogenreduct
technolog
use
riboflavin
need
unintend
benefici
result
nucleicacidalt
pathogenreduct
technolog
process
also
inactiv
white
blood
cell
caus
transfusionassoci
graftversushost
diseas
tagvhd
sever
studi
use
mice
demonstr
effici
pathogenreduct
technolog
prevent
gvhd
grass
et
al
compar
amotosalen
pct
gamma
irradi
experi
use
strain
mice
strain
mice
homozyg
locu
wherea
mice
heterozyg
spleen
donor
mice
collect
process
produc
splenocyt
suspens
treat
one
three
way
onethird
suspens
treat
gamma
irradi
onethird
treat
amotosalen
pct
onethird
untreat
recipi
mice
strain
receiv
transfus
one
three
suspens
suspens
splenocyt
anoth
mous
control
sever
featur
gvhd
follow
sever
week
receiv
untreat
cell
develop
gvhd
character
splenomegali
decreas
bodi
weight
decreas
skin
integr
pancytopenia
anim
kill
organ
examin
histolog
evid
gvhd
addit
donor
cell
engraft
demonstr
flow
cytometri
none
mice
receiv
product
treat
gamma
irradi
amotosalen
pct
develop
gvhd
six
mice
receiv
untreat
product
develop
gvhd
addit
mousebas
studi
demonstr
effici
prevent
gvhd
riboflavin
demonstr
effect
use
cell
cultur
jurkat
cell
thu
base
exist
data
pathogenreduct
technolog
disrupt
nucleic
acid
also
appear
prevent
tagvhd
pathogenreduct
technolog
show
great
promis
make
blood
suppli
safer
inde
prtreat
product
use
clinic
howev
pr
technolog
risk
free
learn
pathogen
infect
blood
suppli
realiz
pathogen
fulli
inactiv
accordingli
unlik
current
practic
test
pathogen
elimin
full
clinic
role
pr
technolog
field
transfus
medicin
remain
determin
